Novavax, Inc.
NASDAQNovavax is one of the more unusual setups in biotech right now — a stock that has rallied 38% in a month while carrying one of the heaviest short positions in the sector, with borrowing conditions tightening sharply just as the price pushes higher. The short position here is genuinely large. Short interest runs at roughly 27.7% of free float, with around 45 million shares sold…
NVAX utilization surges to 90.66%, highest level in nearly a year, as short interest holds firm at 28% of float.
Novavax is one of the more unusual setups in biotech right now — a stock that has rallied 38% in a month while carrying one of the heaviest short positions in the sector, with borrowing conditions tightening sharply…
Novavax heads into the back half of August with one of the most persistent short positions in US biotech — and a borrow market that just shifted gears in a way worth watching. Short interest is the defining feature of…
Snapshot as of 20 Sept 2026
Novavax reports Q1 2026 results on May 8 with one of the most extreme short-side setups in the biotech universe — yet a sharp rally into the print has already squeezed a portion of those bears. The lending market is…
NVAX just delivered one of its cleaner earnings surprises in recent memory — Q1 revenue of $139.5M crushed the $78.3M consensus estimate, and a loss of $0.06 per share came in $0.17 better than expected. The stock…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NVAX — free to start on ORTEX.
Sign up for free →Open NVAX on ORTEX